Keyword: Takeda

Lenvima's quarterly sales grow to $106 million; China makes 48-drug list for streamlined review; Samsung commits further investment in biologics.

Shire could fill Takeda's gap of late-stage assets; GSK lays off 1,000 as a Bangladesh plant nears closure; Laekna gets two Novartis cancer drugs.

Takeda needs to replace sinking Velcade revenue, but it has just three late-stage drugs while Shire has about a dozen.

Eisai and Biogen's recent Alzheimer's data spark debate; Beijing works to contain a vaccine scandal; BMS and Tsinghua University pen drug discovery pact.

Takeda's Alunbrig now sits in the back seat in ALK+ lung cancer, behind rivals from Pfizer, Novartis and Roche—but some new data could help change that.

Pfizer halts production at a legacy Hospira plant; China works to offer Indian drugmakers streamlined access; Roivant's Sinovant debuts with 11 assets.

Takeda's $585 million Chinese revenue for FY2017 was only one-tenth of what it collected from Japan, and buying Shire won't change that soon.

J&J and Allergan are among the pharma companies mulling both acquisitions and selloffs, signaling that the M&A boom will continue through 2018.

Sanofi launches a big data-focused global R&D hub in China; Takeda looks to sell its old HQ for $542 million; I-Mab gets $220 million in series C.

After opening its new global headquarters in Tokyo, Takeda is seeking buyers for its old headquarters in Osaka to help fund its Shire takeover.